Pharma giant GlaxoSmithKline (GSK) has been fined almost £300 million after a Chinese court found it guilty of bribery.
The penalty, a £297m (3 billion RMB) fine, follows allegations that the drug company’s Chinese operation GSK China Investment Co (GSKCI) paid bribes to doctors and hospitals in order to have their products promoted.

To read the full article, please follow this link to the website of our media member Conference and Travel Publications Ltd.